🇺🇸 FDA
Patent

US 11752202

Compositions and methods for treating hemoglobinopathies

granted A61KA61K31/7088A61K35/15

Quick answer

US patent 11752202 (Compositions and methods for treating hemoglobinopathies) held by Beam Therapeutics Inc. expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Beam Therapeutics Inc.
Grant date
Tue Sep 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
28
CPC classes
A61K, A61K31/7088, A61K35/15, A61K35/18, A61K35/28